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Abstract
Introduction: HIV eradication and remission research has largely taken place in high-income countries. In low- and middle-
income countries (LMIC), there may be factors that have a substantial impact on the size of the latent HIV reservoir and the
immunological response to infection. If a curative strategy is to be available to all HIV-infected individuals, these factors must
be understood.
Methods: We use a scoping review to examine the literature on biological factors that may have an impact on HIV
persistence in LMIC. Three databases were searched without date restrictions.
Results: Uncontrolled viral replication and higher coinfection prevalence may alter the immunological milieu of individuals in
LMIC and increase the size of the HIV reservoir. Differences in HIV subtype could also influence the measurement and size of
the HIV reservoir. Immune activation may differ due to late presentation to care, presence of chronic infections, increased
gut translocation of bacterial products and poor nutrition.
Conclusions: Research on HIV remission is urgently needed in LMIC. Research into chronic immune activation in resource
poor environments, the immune response to infection, the mechanisms of HIV persistence and latency in different viral
clades and the effect of the microbiological milieu must be performed. Geographic differences, which may be substantial and
may delay access to curative strategies, should be identified.
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Introduction
Access to antiretroviral therapy (ART) has improved the
lives of millions affected by HIV, but HIV remains incurable.
In 2015, there were an estimated 36 million people living
with HIV (PLHIV), most of whom live in low- and middle-
income countries (LMIC). Worldwide, approximately half of
HIV-infected individuals accessed HIV treatment but there
are wide differences between countries in the number of
HIV-infected individuals on treatment [1]. Recent data have
spurred the World Health Organization (WHO) to recom-
mend ART for all HIV-infected individuals [2]; thus, there
will be more individuals receiving treatment in the near to
medium future. HIV treatment is lifelong and strict adher-
ence to treatment regimens is required for successful ther-
apy. The burden of care for treatment programmes in
countries with limited resources is enormous and will con-
tinue to grow. Moreover, the immunological damage due to
HIV infection and ongoing viral replication leads to a cas-
cade of events that are associated with important nonin-
fectious morbidities which will likely stress healthcare
resources even further. Sustained remission of HIV without
the need for ART, if attainable, will be critical to the overall
health of the population and will allow for a broader dis-
tribution of resources.
The cure of the “Berlin patient” combined with prolonged
remission in a relative large proportion of early treated indi-
viduals in the Visconti cohort and SPARTAC trial has led to
enthusiasm for clinical research that aims to achieve HIV
remission without continued need for ART. Total eradication
of HIV remains a long term but challenging goal. Clinical
research in HIV remission and cure research has largely
occurred in resource-rich settings where the epidemic is dri-
ven by men who have sex with men. In many LMIC, women
and children are especially affected by the epidemic.
Worldwide, women comprise more than half of all adults
living with HIV [3] and there are an estimated 1.8 million
children living with HIV [4]. There are important differences
in viral strains, HIV-infected populations and the clinical con-
text between resource-rich settings and LMIC. These differ-
ences are poorly understood and may be an important barrier
to successfully achieving sustained remission or eradication.
The size of the pool of latently infected cells, the immune
response and viral factors associated with different HIV sub-
types may all be important. Indeed, a recent modelling exer-
cise suggested that a cure might be cost-effective in LMIC [5].
If cure research is to reach all HIV-infected people, these
differences need to be evaluated and assessed well ahead of
any potential interventions. Sex differences that may be
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important have already been reviewed in this journal [6]. This
article focuses on biological factors that may be important in
eradication research that are different in different geographic
environments.
A critical barrier to achieving sustained remission of HIV is
the presence of long-lived latently infected memory CD4+ T
cells that contain replication competent HIV DNA, the “reser-
voir”. A first step towards remission is reducing the reservoir.
Factors affecting the reservoir size have not entirely been
elucidated, but in LMIC, late presentation to care, the pre-
sence of chronic infections causing immune activation and
chronic inflammation, increased gut translocation of specific
bacterial products and poor nutrition which attenuates the
response to infections may be important determinants of the
size of the HIV reservoir and may be different in resource-
rich and resource-limited environments.
Methods
We used a scoping review to examine the literature using
Arksey and O’Malley’s framework [7]. Scoping studies sum-
marize key evidence on a topic but do not go through the
process of a formal systematic review. We searched the fol-
lowing databases: MEDLINE (OVID interface, 1946 onwards),
EMBASE (OVID interface, 1947 onwards) and the Cochrane
Library. We reviewed this literature to explore biological dif-
ferences between resource rich and LMIC, focusing on poten-
tial differences in the HIV reservoir. No ethics approval was
required because this was not human subjects research.
Immune activation and inflammation
Pre-ART immune activation and inflammation pose an
important barrier to reservoir eradication, in several ways:
First, inflammation may increase the size and persistence of
reservoirs. Patients with higher levels of inflammation and
activation before ART initiation have long-lasting higher
levels of persisting HIV-infected cells and HIV cell associated
RNA [8]. Moreover, chronic inflammation, associated with
T-cell activation and proliferation, may result in an
increased number of cells harbouring replication competent
HIV [9–11]. Immune stimulation also causes lymphoid
hyperplasia locally, and the lymphoid follicle has now
been shown to be critical to HIV persistence [12].
Integrated HIV DNA, localized in T follicular helper cells
within the B-cell follicle, are inaccessible to immune killing
at least in part because there are few cytotoxic T lympho-
cytes (CTLs) with a CD8 phenotype in this compartment.
Second, inflammation may limit killing of infected cells,
which is an important component of the “kick and kill
strategy” for reservoir reduction. T-cell exhaustion, the
progressive and irreversible loss of T-cell function, is char-
acterized by decreased effector function, a change in the
ability to respond to different antigens and sustained
expression of inhibitory receptors such as the checkpoint
molecules (for example PD1 and LAG 3) [13–17]. Chronic
immune activation is associated with bystander killing of
CD4 cells and exhaustion of HIV-1-specific CD4 and CTLs
[16,18–20]. Importantly, expression of these markers of
immune exhaustion is associated with higher levels of inte-
grated DNA and a more rapid virological rebound in a
cohort interrupting therapy suggesting that this process is
also associated with an expanded HIV reservoir size [21].
Exhausted CD8 cells are unable to kill HIV-infected cells
even when latency is reversed and infected cells express
CTL epitopes [22]. While cytokine secretion improves and
expression of PD-1 decreases in the presence of durable,
suppressive ART [23], functional capacity is not fully
restored and multiparametric T-cell pathology persists,
despite early initiation of ART [24].
Figure 1. Effects on HIV Reservoir Size in Resource Limited Settings
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Uncontrolled HIV
Uncontrolled viral replication is probably the most impor-
tant factor driving increased immune activation and inflam-
mation in LMIC. Despite changes in guidelines which now
recommend therapy for all HIV-infected individuals, full
access to HIV treatment is limited. In South Africa, for
example, of the estimated 7 million HIV-infected people,
only approximately 3 million were on therapy in 2015 [25].
Even when guidelines recommend initiation of therapy, late
presentation to care is common. A recent meta-analysis
documented profound immunosuppression at ART initiation
in many sub-Saharan African countries [26,27]. In addition,
although viral load monitoring for clinical care is now
recommended, it is not universally available and even
when it is available, it is often not acted upon [28].
Uncontrolled HIV replication is associated with a heigh-
tened state of inflammation due to both HIV itself and
the presence of other infections which are poorly con-
trolled in the setting of immune suppression.
ART initiation at low CD4 counts is often indicative of a
prolonged period of uncontrolled HIV and is associated with
a greater degree of immune activation [29]. Immune recon-
stitution is incomplete even after ART has rendered the
viral load undetectable, shown in both resource rich and
resource poor environments, though there are no direct
comparisons [30,31]. Importantly, very early therapy may
protect mucosa-associated immune tissue, limit reservoir
seeding, prevent CTL escape and retain functional CD4
and CD8 HIV-1 immune responses [32]. Recent work from
Thailand has attempted to identify the specific immune
lesions in the setting of acute infection and has found
that acute HIV infection is associated with increased levels
of the biomarkers of intestinal damage, inflammation, coa-
gulation and fibrosis [31]. With suppressive ART initiated
during acute HIV infection, the procoagulant state nor-
malizes but gut damage persists and monocyte activation,
systemic inflammation and fibrosis remain increased, albeit
lower than in individuals starting ART in chronic HIV infec-
tion. Importantly, increases in CD4 T-cell populations corre-
late with decreases in specific markers of immune activation
[33]. The notion that immune damage persists after the
initial insult was confirmed in a study of biomarkers in the
United States [34], and recent data from the AIDS clinical
trials group suggest that HIV levels correlate with inflamma-
tion and activation before starting therapy but not during
long-term suppressive therapy, suggesting that HIV reservoir
size is related to factors present before ART initiation [8].
CD8 activation has an important impact on CD4 T-cell recov-
ery [35] and a low CD4/CD8 ratio correlates with T-cell
activation; those who start treatment with a low ratio are
less likely to normalize over time [36]. The absence of
immune exhaustion and premature immune senescence
may increase the ability to respond to future therapeutic
interventions designed to induce HIV remission [32].
Viral subtype
Viral subtype may be important in HIV persistence. Globally,
subtype C represents about half of all infections and is by
far the most common subtype found in LMIC. Subtype B
accounts for only approximately 12% of all infections world-
wide [37] but the majority of remission-related research is
done in patients infected with subtype B virus and there
may be significant differences. The HIV tat protein is critical
to transcriptional activity and may play an important role in
establishing and maintaining latency [38]. Pronounced dif-
ferences in clade B and C tat protein have been identified
[39]; the significance of this to cure strategies has not yet
been determined. Investigations into the differences in
neurological complications of HIV have revealed that clade
C virus is associated with a very different inflammatory
environment in the central nervous system and is asso-
ciated with the expression of different cytokines such as
IL-33, leading to different rates of apoptosis of cells
infected with clade C virus [40]. Ongoing studies are eval-
uating the cytokine profiles in patients infected with differ-
ent subtypes and the differences may be profound [41]. HIV
LTR promotors, which are different in different clades,
affect transcription of cellular genes. Induction of HIV-1
subtype C viral production may be more responsive to a
cellular inflammatory milieu, in particular TNFα production
due to an additional NF-κB element in its long terminal
repeat (LTR) promoter region [42]. When studying various
subtypes and inter-subtype recombinants in Tanzania, sub-
type C LTR was also associated with a sixfold increased risk
of HIV mother to child transmission [43], CD4 cells with HIV
DNA integrated near growth genes may proliferate more
than other HIV-infected or uninfected cells [44,45]. Studies
of cells with identical viral integration sites, indicative of
clonal expansion, are currently limited to resource-rich set-
tings and significant differences may exist in LMIC; this is an
important knowledge gap that requires research.
Importantly, after years on treatment, the integration site
repertoire may be affected by the pervasive CD4 cell milieu
which may differ in patients with high levels of chronic
immune stimulation. It is unknown whether there is link
between viral integration and a particular cytokine milieu
that affects CD4 proliferation, stimulation and differentia-
tion [46].
Chronic infections
Many bacterial, viral, and parasitic infections are diseases
of poverty and are more common in LMIC. The immune
response to these infections may influence the HIV reser-
voir size when pathogen-specific HIV-infected cells expand
in response to antigen stimulation. Chronic antigenic expo-
sure stimulates a broad adaptive and innate immune
response. Bacterial infections stimulate reactive lymphoid
hyperplasia and growth of local lymph nodes and viral
pathogens cause a non-specific T-cell activation that may
contribute to the proliferation of T cells containing replica-
tion competent HIV. Mounting evidence suggests that
macrophages may be infected with HIV and serve as a
critical HIV reservoir, most importantly in the central ner-
vous system [47]. The macrophage has diverse roles in host
immunity and may be important in the immunopathogen-
esis of chronic bacterial infections such as tuberculosis (TB).
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Specific examples of pathogens that are more common in
LMIC and affect the populations most impacted by the
epidemic may be illustrative of mechanisms that are impor-
tant in establishing and maintaining the HIV reservoir.
Tuberculosis (TB)
TB is the most clinically important coinfection for PLHIV in
LMIC and is the leading cause of death among PLHIV world-
wide [48]. The immune response to TB is characterized by a
sustained inflammatory response that persists in many
individuals even after therapy for TB has been completed
[49]. T-cell activation, as measured by elevated CD38 and
HLA-DR expression on CD4+ and CD8+ T-lymphocytes, is
described in both latent TB infection and in active TB
disease [50]. These lymphocytes can harbour replication
competent HIV DNA but it is unknown whether the expan-
sion of these cells in the setting of TB is associated with an
increased reservoir size. TB overcomes the intracellular kill-
ing mechanisms of the host macrophage’s defences and
there may be a synergistic relationship between HIV and
TB in which the autophagic pathways are disrupted leading
to increased longevity of HIV-infected cells and increased
replication of TB in macrophages [51].
Sexually transmitted bacterial infections
LMIC often have a higher burden of sexually transmitted
infections (STIs) and it is plausible that STI coinfection may
increase the size of the active HIV reservoir. WHO data-
bases show that antenatal syphilis is more common in LMIC
[52]. A systematic review found that 91% of incident infec-
tions of chlamydia, gonorrhoea and trichomonas were from
individuals in LMIC [53], a finding confirmed by the Global
Burden of Disease 2013 Study [54]. Similarly, trichomonas
infection is disproportionately found in LMIC [53].
Coinfection with STIs is associated with HIV shedding even
when HIV is adequately controlled [55]. One study identi-
fied approximately a 2.5-fold risk of HIV shedding in the
setting of chlamydia and gonorrhoea in women and a
specific cytokine profile in the female genital tract asso-
ciated with HIV shedding that is also associated with
recruitment of CD4 T cells in women seroconverting to
HIV [56]. Several studies have found greater HIV shedding
in individuals with HIV–trichomonas coinfection [57,58].
Among women with HIV–trichomonas coinfection, tricho-
monas treatment reduced vaginal HIV shedding at three
months post-treatment [58]. Another study from Kenya
found a fourfold decrease in vaginal HIV shedding after
trichomonas treatment [59]. Both studies included coin-
fected women who had undetectable HIV viral load in
plasma but detectable viral shedding in the genital tract.
Although we do not know the implications of these trends
for latency, increased shedding may be reflective of an
active mucosal reservoir which could pose challenges for
immune control and reservoir reduction. Recent work in
HIV-uninfected women documented recruitment of poten-
tial reservoir cells into the genital tract in women with
concomitant STIs, lending credence to the notion that
local inflammation may be associated with an expansion
of cells that could contain replication competent HIV
[60,61]. This is an area that requires further study.
Other encapsulated bacteria
Streptococcus pneumoniae (pneumococcus) and
Haemophilus influenzae are important pathogens and
have a huge disease burden in both HIV-infected and unin-
fected children. Nasopharyngeal carriage of pneumococcus
has been studied in the context of studies of the conju-
gated pneumococcal vaccine. The prevalence of pneumo-
coccal carriage was as high as 93% in young children [62] in
LMIC. In contrast, the highest rates described in resource-
rich countries were 50.8% [63]. Higher rates of CD4 cells
with memory and effector phenotypes have been described
in adenoidal tissue of children colonized with pneumococ-
cus [64]. Rates of H. influenzae carriage in HIV-infected
children in India were double that of uninfected children
[65]. As described above, lymphoid tissue plays a major role
in HIV persistence as lymph node follicles are a major HIV
reservoir site [14]. The relationship between oropharyngeal
carriage of bacterial pathogens, including pneumococcus,
and the size of the local HIV reservoir in oropharyngeal
mucosa is entirely unknown but may be significant. Given
the population structure of the HIV epidemic in LMIC is
important to study.
Viral infections
Chronic viral infections are associated with immune acti-
vation and inflammation and are postulated to play an
important role in HIV persistence. Modelling research
suggests that Africa has a higher burden of both herpes
simplex type 2 [66] and herpes simplex type 1 [67]
compared to other regions of the world. Other herpes-
viruses, such as cytomegalovirus (CMV), Epstein Barr
virus (EBV) and Kaposi’s sarcoma-associated herpesvirus
(KSHV), are endemic in many developing countries
[68,69]. CMV seroprevalence approaches 100% in adults
in sub-Saharan Africa [70] and EBV and KSHV infections
are often acquired very early in life. The role of herpes
viruses has been studied in the context of HIV persis-
tence. Asymptomatic shedding of both EBV and CMV
viruses is more common in individuals infected with
HIV, and recent work has associated more frequent shed-
ding of these viruses in virally suppressed HIV-infected
individuals with a larger HIV reservoir [71]. The greatest
burden of hepatitis B infection and hepatitis C infection
is in LMIC [72–74]. The population attributable fraction
for human papillomavirus is 6.9% in less developed
regions of the world and 2.1% in more developed regions
[75]. The relationship between the HIV reservoir and
these viruses is unknown but recent work has shown
an association with both inflammatory markers and
expansion of T cells with activation and exhaustion mar-
kers in women who are dually infected with HIV and HPV
[76,77].
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Helminths and other parasites
There is significant geographic overlap between the com-
munities most affected by HIV and helminthic infections.
The immunopathology of helminthic infection is complex;
they stimulate immune responses via tissue damage and
egg production during acute infection but have evolved
mechanisms of immune evasion, often using regulatory
immune mechanisms. A common feature of all helminthic
infections is Th1/Th17-mediated inflammation and Th2-
dependent pathology [78,79]. Th2 cells orchestrate the
protective immunity against worm infections but, at the
same time, the T-regulatory cells induced by helminths
appear to attenuate Th2 responses that mediate allergy
and autoimmune diseases [80]. Increased levels of immu-
nosuppressive cytokines such as IL-10 and TGF-β1 have
been demonstrated [81]. Helminthic infections are asso-
ciated with the expression of markers of T cell exhaustion
[82] and it is plausible that helminthic infestations may
contribute to an expansion of the pool of latently infected
cells.
Microbial translocation
One of the key drivers of immune activation in HIV infec-
tion is considered to be translocation of intestinal organ-
isms because of early disruption of the intestinal epithelial
barrier, due to preferential infection and depletion of CCR5-
expressing CD4+ T lymphocytes in the gut associated lym-
phoid tissue. Portal circulation of these gut organisms may
contribute to immune activation [83–87]. Binding of micro-
bial-associated molecular patterns, such as peptidoglycan,
lipopolysaccharide, flagellin and CpG DNA, to pattern recog-
nition receptors, activates a signalling cascade in innate
immune cells, resulting in the production of pro-inflamma-
tory cytokines, such as interleukin (IL)-1β, IL-6, tumour
necrosis factor and type 1 interferons [88,89].
Very early initiation of ART (during stage FI/II) has been
shown to maintain the mucosal barrier and fully reverse the
initial mucosal and systemic immune activation, most likely
through preservation of mucosal CD4+ Th17 cells [90].
The role of intestinal microbiota in aggravating or ameli-
orating microbial translocation is increasingly recognized
[91–93]. HIV has been associated with “bidirectional unba-
lances [sic]” in metabolic activity of the intestine, poten-
tially affecting the integrity and function of the mucosal
barrier as well as local and systemic inflammation [94].
More severe immunosuppression is associated with low
diversity microbiota and increased immune activation
[95,96] that is present even in people on ART. In LMIC,
poor sanitation and hygiene, persistent diarrhoea, inade-
quate diet and severe acute malnutrition have been
described [97] and are associated with inflammation of
the small intestine, reduced absorptive capacity, increased
intestinal permeability and subsequent increased microbial
translocation. Very few studies have examined whether
microbial translocation differs between persons living in
resource-limited and resource-rich settings. In one study,
products of gut translocation were found to be higher in
HIV-infected patients from Vietnam and Ethiopia compared
to Swedish patients. The researchers proposed in addition
to the factors described above that HIV subtype may play a
role [98].
Nutrition
The contribution of nutrition to immunological health can-
not be overstated [99]. Inadequate dietary intake leads to a
loss of epithelial integrity in the skin, histologically charac-
terized by atrophy and a cutaneous inflammatory response.
Malnutrition-associated enteropathy compromises the
intestinal barrier function and is accompanied by an inflam-
matory mucosal infiltrate [100,101]. A Th2 response has
been noted and a state of heightened inflammation has
been postulated, although a greater proportion of activated
T cells has not been found. Intestinal infections, common in
LMIC, contribute to micronutrient malabsorption. Vitamins
and other micronutrients have been implicated in disease
progression and may be important in the microenviron-
ment in which cellular signalling occurs [102,103]. The
specific defects that may affect HIV persistence are entirely
unknown.
Laboratory evaluation of the reservoir
There is no universally agreed method for evaluating the
size of the latent HIV reservoir [104–106] and different
methods either under- or overestimate the pool of cells
that contain replication competent DNA. Although often
regarded as the gold standard for HIV reservoir assays, as
it detects replication competence, the quantitative viral
outgrowth assay (QVOA) has significant limitations. It is
expensive, cumbersome and requires a large volume of
blood and biosafety level 3 procedures. Cell viability is
affected by variable processing and storage conditions,
although these have improved with standardized proce-
dures and quality management [107]. QVOA may under-
estimate the number of intact proviruses by 25–27-fold.
Only a small proportion of intact proviruses are inducible
after one round of stimulation, with additional proviruses
being induced after a second round of stimulation
[108,109]. Samples that are QVOA negative have been
shown to bear infectious virus when using humanized
mice for viral recovery [110] and patients who tested nega-
tive on QVOA had viral rebound after therapy cessation
[111]. Importantly, assay sensitivity is dependent on draw-
ing large volumes of blood to isolate a sufficient number of
CD4 cells. Alternative, more practicable assays of inducible
provirus are the total virus recovery assay [112] and Tat/rev
Induced Limiting Dilution Assay [104]. Although these
assays could be useful in monitoring patients receiving
curative interventions, they require virus culture facilities
and have the limitation that inducible virus does not prove
replication competence. Molecular assays of HIV nucleic
acid do not require culture facilities and may be more
feasible to perform in LMIC: assays of total or integrated
HIV DNA can be performed on smaller sample volumes but
may severely overestimate the infectious or true reservoir
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[108]. Low copy viremia detected by a single copy HIV-1
plasma RNA assay correlates well with QVOA but is unde-
tectable in a large proportion of patients [113]. The evalua-
tion of tissue, including lymph nodes and other pathological
specimens, requires substantial clinical and laboratory infra-
structure which are not available in many LMIC facilities
[114,115]. In addition to the above, PCR-based assays
require validation across various subtypes and uniform
reporting against a reference standard such as the number
of cells assayed is required.
Community response
Community acceptance is critical to a successful cure strat-
egy [116]. Stakeholder engagement among a diverse group
of individuals from different local contexts was identified as
a priority by the International AIDS Society [117]; yet,
communities in regions most affected by the epidemic do
not have input into cure studies. Some of the concepts are
complex, and messaging needs to be carefully tailored to
the specific audience [118]; however, attitudes that suggest
that the principles cannot be understood are divisive, pre-
sumptuous and unhelpful. HIV remission research will need
to be integrated within existing HIV prevention and treat-
ment strategies and prioritized within the context of the
overall goal of ending the epidemic. It is likely that focus on
immediate prevention and treatment goals is deemed more
attainable and more practical than cure goals, but as the
field moves forward, access to curative strategies may be
delayed because of the need for local safety and efficacy
data. Importantly, lack of meaningful participation through
mechanisms such as advisory boards could ultimately affect
the acceptability of remission strategies [119]. Preparatory
research must be implemented in LMIC or the majority of
PLHIV globally will not have access to this important
strategy.
Conclusion
The inclusion of patients from high burden LMIC is
essential for cure research. HIV subtype diversity, differ-
ences in inflammation and concurrent infections, may
have an important impact on the size and cell and
tissue distribution of the reservoir. The inclusion of
patients from high burden LMIC is essential for cure
research. Curative strategies that rely on immune func-
tion may be sensitive to differences in immune exhaus-
tion, and the determinants of immune exhaustion in
diverse settings need to be studied. We outline specific
areas for research (Table 1), but it is clear that including
patients from LMIC early in the process of clinical
research might then accelerate the gradual process of
scaling up an effective HIV cure in the future. In the
SPARTAC study, a high proportion (22.7%) of early trea-
ted African patients achieved post-therapy control [120]
demonstrating that treatment goals are feasible and
acceptable. Early treatment would reduce the burden
of opportunistic infections associated with delayed
initiation and prevent onward transmission from early
acute hyper-infectious individuals. Such an approach
towards remission should be prioritized in LMIC.
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